NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Metro Bank PLC (OTCMKTS: MBNKF)

Lawsuit on behalf of: investors who purchased March 6, 2018 – May 1, 2019
Lead Plaintiff Deadline : July 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/metro-bank-plc-loss-form?prid=2616&wire=1

According to the filed complaint, during the class period, Metro Bank PLC made materially false and/or misleading statements and/or failed to disclose that: (1) Metro Bank misclassified the risk terms of many of its loans; (2) accordingly, Metro Bank failed to maintain sufficient capital; (3) this conduct would lead to investigations by the PRA and FCA; (4) this conduct would also lead to the reduction of deposits at Metro Bank from larger commercial and partnership clients; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

Ra Medical Systems, Inc. (NYSE: RMED)

Lawsuit on behalf of: investors who purchased stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.
Lead Plaintiff Deadline : August 6, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ra-medical-systems-inc-loss-form?prid=2616&wire=1

According to the filed complaint, (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Pyxus International, Inc. (NYSE: PYX)

Lawsuit on behalf of: investors who purchased on behalf of stockholders who purchased Pyxus (f/k/a Alliance One International, Inc. (AOI)) securities between June 7, 2018 and November 8, 2018, inclusive.
Lead Plaintiff Deadline : August 6, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pyxus-international-inc-f-k-a-alliance-one-international-inc-loss-form?prid=2616&wire=1

According to the filed complaint, (1) the Company was experiencing longer shipping cycles; (2) as a result, the Company’s financial results would be materially affected; (3) the Company lacked adequate internal control over financial reporting; (4) the Company’s accounting policies were reasonably likely to lead to regulatory scrutiny; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 553517

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Community Health Systems, Inc. (“Community Health” or the “Company”) (NYSE: CYH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Community Health securities between February 20, 2017 and February 27, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/cyh.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Community Health had understated its contractual allowances; (2) Community Health had understated its provision for bad debts; (3) Community Health had overstated its net operating revenue; (4) Community Health had understated its net loss; and (5) as a result of the foregoing, defendants’ positive statements about Community Health’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/cyh or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Community Health you have until July 29, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 552741

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verb Technology Company, Inc. (“Verb” or the “Company”) (NASDAQ: VERB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Verb securities from January 3, 2018 and May 2, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/verb.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that on January 3, 2018, Verb revealed a purported agreement with Oracle America, Inc. (the “Oracle Agreement”) and filed Form 8-K with the United States Securities and Exchange Commission omitting the text of the agreement itself. The complaint continues to allege that throughout the Class Period, Verb continued to hype this relationship. During this time, Verb stock price increased over 200% up from $0.12 per share on January 3, 2018 to $2.70 on April 19, 2018.

Then on April 23, 2018, Verb revealed the actual terms of the Oracle Agreement through the filing of a Form 8-K. The complaint alleges that the terms of the agreement exposed that the prior representations regarding the scope of the relationship with Oracle were materially misleading. Following this news, Verb stock dropped 43% from the previous week to close on April 30, 2018 at $1.54 per share. The stock continued to drop and and closed at $3.04 per share on April 20th.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/verb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Verb you have until September 9, 2019to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 552771

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

FedEx Corporation (NYSE: FDX)
Class Period: September 19, 2017 – December 18, 2018
Deadline: August 26, 2019
For more info: www.bgandg.com/fdx

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) TNT’s overall package volume growth was slowing as TNT’s large customers permanently took their business to competitors after the Cyberattack; (ii) as a result of the customer attrition, TNT was experiencing an increased shift in product mix from higher-margin parcel services to lower-margin freight services; (iii) the anticipated costs and timeframe to integrate and restore the TNT network were significantly larger and longer than disclosed; (iv) FedEx was not on track to achieve the TNT Income Improvement Target; and (v) as a result of these undisclosed negative trends and cost issues, FedEx’s positive statements about TNT’s recovery from the Cyberattack, integration into FedEx’s legacy operations, customer mix, customer service levels, profitability, and prospects lacked a reasonable basis.

Acer Therapeutics Inc. (NASDAQ: ACER)
Class Period: September 25, 2017 – June 24, 2019
Deadline: August 30, 2019
For more info: www.bgandg.com/acer

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Acer lacked sufficient data to support filing EDSIVO’s NDA with the FDA for the treatment of vEDS; (2) the Ong Trial was an inadequate and ill-controlled clinical study by FDA standards, and was comprised of an insufficiently small group size to support EDSIVO’s NDA; (3) consequently, the FDA would likely reject EDSIVO’s NDA; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Diebold Nixdorf, Incorporated (NYSE: DBD)
Class Period: May 4, 2017 – July 4, 2017
Deadline: September 3, 2019
For more info: www.bgandg.com/dbd

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing delays in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle; (2) the foregoing issues were negatively impacting the Company’s services business and operations; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 552767

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Sunlands Technology Group (NYSE: STG)
Class Period: securities purchased pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Sunlands’s March 2018 initial public stock offering (the “IPO” or the “Offering”)
Deadline: August 26, 2019
For more info: www.bgandg.com/stg

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Sunlands’s student enrollment was declining; (2) Sunlands’s gross billings were declining; (3) Sunlands’s marketing tactics were not as robust as described in the Registration Statement; and (4) as a result, defendants’ statements about Sunlands’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

EQT Corporation (NYSE: EQT)
Class Period: June 19, 2017 – October 24, 2018
Deadline: August 26, 2019
For more info: www.bgandg.com/eqt

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) land acquired by the Rice Energy merger was not contiguous with the Company’s previously held acreage, which reduced the purported synergy benefits; (2) the purported longer lateral wells were not feasible because of intervening third-party parcels or prior drilling by EQT, Rice, or third parties; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Fred’s Inc. (NASDAQ: FRED)
Class Period: December 20, 2016 – June 28, 2017
Deadline: August 27, 2019
For more info: www.bgandg.com/fred

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the Original Merger, as well as, the Revised Merger; and (2) representing that inside knowledge of the FTC gave confidence that the deal would close.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 552764

WILMINGTON, DE / ACCESSWIRE / July 26, 2019 / Rigrodsky & Long, P.A.:

Do you, or did you, own shares of L Brands, Inc. (NYSE: LB)?

Did you purchase your shares between May 31, 2018 and November 19, 2018, inclusive?

Did you lose money in your investment?

Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Southern District of Ohio on behalf of all persons or entities that purchased the common stock of L Brands, Inc. (“L Brands” or the “Company”) (NYSE: LB) between May 31, 2018 and November 19, 2018, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).

If you purchased shares of L Brands during the Class Period, or purchased shares prior to the Class Period and still hold L Brands, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Seth D. Rigrodsky or Timothy J. MacFall at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at info@rl-legal.com, or at http://rigrodskylong.com/contact-us/.

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that, prior to and during the Class Period, L Brands’ Victoria’s Secret and PINK businesses began to experience deteriorating operating performance due to, among other things, increased competition from new lingerie brands. In an attempt to drive sales and retain market share in the face of increasing competition, Victoria’s Secret and PINK engaged in heavy promotional activities by offering consumers large discounts and even giving items free of charge. While this marketing strategy helped to mitigate sales declines, it adversely impacted the Company’s profit margins and cash flows and had a deleterious impact on the Company’s liquidity. In response to questions from securities analysts about the sustainability of the Company’s dividends, defendants repeatedly stated that L Brands had sufficient cash flow and cash on hand to sustain its dividends and that the Company, “in its history, ha[d] never reduced the dividend.” As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.

According to the Complaint, on November 19, 2018, just weeks after defendants issued a series of false and misleading statements about the Company’s dividends, L Brands announced that it was cutting its dividend in half so that it could pay down existing debt.

On this news, shares of L Brands declined over 17%, closing at $28.43 per share on November 20, 2018, on heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than September 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Timothy J. MacFall
(888) 969-4242
(516) 683-3516
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long, P.A.

ReleaseID: 553516

WILMINGTON, DE / ACCESSWIRE / July 26, 2019 / Rigrodsky & Long, P.A.:

Do you, or did you, own shares of Eagle Bancorp, Inc. (NASDAQ CM: EGBN)?

Did you purchase your shares between March 2, 2015 and July 17, 2019, inclusive?

Did you lose money in your investment?

Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of Eagle Bancorp, Inc. (“Eagle Bancorp” or the “Company”) (NASDAQ CM: EGBN) between March 2, 2015 and July 17, 2019, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).

If you purchased shares of Eagle Bancorp during the Class Period, or purchased shares prior to the Class Period and still hold Eagle Bancorp, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Seth D. Rigrodsky or Timothy J. MacFall at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at info@rl-legal.com, or at http://rigrodskylong.com/contact-us/.

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.

According to the Complaint, on July 17, 2019, Eagle Bancorp disclosed rising legal costs stemming from ongoing internal and government investigations of “the Company’s identification, classification and disclosure of related party transactions; the retirement of certain former officers and directors; and the relationship of the Company and certain of its former officers and directors with a local public official.”

On this news, shares of Eagle Bancorp declined over 26%, closing at $39.10 per share on July 18, 2019, on heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than September 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Timothy J. MacFall
(888) 969-4242
(516) 683-3516
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long P.A.

ReleaseID: 553515

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Anheuser-Busch InBev SA/NV (NYSE: BUD)
Class Period: March 1, 2018 – October 24, 2018
Deadline: August 20, 2019
For more info: www.bgandg.com/bud

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants’ cost cutting measures had largely run their course; (2) the devaluation of key emerging market currencies and input cost inflation was having a material adverse effect on Anheuser-Busch’s margins, EBITDA and profitability; (3) Anheuser-Busch had been experiencing less than expected growth and profits in certain key markets; (4) Anheuser-Busch was not going to be able to maintain its then current dividend and still meet its deleveraging targets; (5) Anheuser-Busch was at risk of having its credit ratings downgraded; (6) as a result, defendants lacked a reasonable basis for their positive statements about the Company’s dividend growth, its cost synergies, its liquidity, and defendants’ then current efforts to deleverage Anheuser-Busch’s balance sheet; (7) the liquidity and working capital disclosures in filings Anheuser-Busch made with the SEC were materially false and misleading; (8) the risk factor disclosures in filings Anheuser-Busch made with the SEC were materially false and misleading; (9) the representations about Anheuser-Busch’s disclosure controls in filings the Company made with the SEC were materially false and misleading; (10) the certifications issued by Defendants Carlos Brito and Felipe Dutra regarding Anheuser-Busch’s disclosure controls and internal controls over financial reporting were materially false and misleading; and (11) based on the foregoing, defendants lacked a reasonable basis for their positive statements about Anheuser-Busch’s then-current business operations and future financial prospects.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
Class Period: August 4, 2017 – May 10, 2019
Deadline: August 20, 2019
For more info: www.bgandg.com/teva

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (2) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (3) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

Helius Medical Technologies, Inc. (NASDAQ: HSDT)
Class Period: November 9, 2017 – April 10, 2019
Deadline: September 9, 2019
For more info: www.bgandg.com/hsdt

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the clinical study on the use of PoNS did not produce statistically significant results regarding the effectiveness of the treatment; (2) that, as a result, the clinical study did not support the Company’s application for regulatory clearance; (3) that, as a result, the Company was unlikely to receive regulatory approval of PoNS; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 552761